Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07614906 · ClinicalTrials.gov registry record
Nitric Oxide Consumption as a Predictor of Vasospasm in Subarachnoid Hemorrhage
A clinical trial, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 40
- Enrollment target
NCT07614906: Recruiting study, sponsored by Massachusetts General Hospital.
NCT07614906 is a clinical trial that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07614906 is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
Study Summary
The goal of this observational study is to understand if angiographic cerebral vasospasm (CV) can be predicted by levels of nitric oxide (NO) consumption in patients with aneurysmal subarachnoid hemorrhage (SAH). To reach this goal, the investigators will compare NO consumption levels in SAH and non-SAH patients. NO consumption levels will be analyzed from samples of participants' cerebral spinal fluid (CSF).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-03-03 |
| Est. Completion | 2027-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07614906
The ClinicalTrials.gov registry entry for NCT07614906 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07614906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07614906 about?
NCT07614906 is a clinical study titled "Nitric Oxide Consumption as a Predictor of Vasospasm in Subarachnoid Hemorrhage". The goal of this observational study is to understand if angiographic cerebral vasospasm (CV) can be predicted by levels of nitric oxide (NO) consumption in patients with aneurysmal subarachnoid hemorrhage (SAH). To reach this goal, the investigators will compare NO consumption levels in SAH and non...
What is the current status of trial NCT07614906?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2024-03-03. Estimated completion is 2027-06.
Who is sponsoring clinical trial NCT07614906?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.